IASLC Profile Banner
IASLC Profile
IASLC

@IASLC

Followers
20K
Following
10K
Media
5K
Statuses
14K

The International Association for the Study of Lung Cancer is the only global organization dedicated solely to the study of lung cancer. #LCSM

Denver, CO
Joined July 2009
Don't wanna be here? Send us removal request.
@IASLC
IASLC
17 hours
On a new episode of Lung Cancer Considered, Dr. @susu_mail0513 moderates a Mandarin-language discussion with Drs. Zhengfei Zhu & Nan Wu on neoadjuvant and perioperative therapy for locally advanced NSCLC in China. ๐Ÿ”—
Tweet media one
0
1
1
@IASLC
IASLC
3 days
WCLC Conference Chair @NReguart discusses how this year's #WCLC25 program builds on multidisciplinary collaboration and global perspectives in thoracic oncology.๐Ÿ”— Read more in ILCN: #LCSM
Tweet media one
0
13
30
@grok
Grok
16 days
Blazing-fast image creation โ€“ using just your voice. Try Grok Imagine.
260
488
3K
@IASLC
IASLC
4 days
On a new episode of Lung Cancer Considered, Dr. @StephenVLiu & Dr. @NarjustFlorezMD sit down with Summer Farmen, Nancee Pronsati & Kirk Smith to discuss highlights from the #ALK+ Summit, patient advocacy & the impact of community. @ALKPositiveinc .๐ŸŽง
Tweet media one
2
4
10
@IASLC
IASLC
4 days
#HT25 Tokyo is where science meets impact!. โœ… Molecular & immune drivers of early #lungcancer.โœ… Biomarkers + AI diagnostics.โœ… Translational science to clinical care.โœ… Emerging therapies to intercept disease. Join the conversation this Nov:
Tweet media one
1
3
8
@IASLC
IASLC
8 days
How is ALK-positive #NSCLC managed in Greece? ๐Ÿ‡ฌ๐Ÿ‡ท. In this episode of #LungCancerConsidered in Greek, @g_mountzios moderates a Virtual Tumor Board with Dr. Petros Christopoulos and @DionysisPastos. ๐ŸŽง . #ALK #LungCancer
Tweet media one
1
4
20
@IASLC
IASLC
10 days
Join us in Chicago, Dec 5โ€“7 for #NACLC25, where leading clinicians, researchers & advocates unite to advance lung cancer care. ๐Ÿ’ก Cutting-edge science.๐Ÿค Networking across disciplines.๐ŸŒ Focus on equity & early detection. Register now: @ASCO. #LungCancer
Tweet media one
2
13
28
@APSRetirement
Alliance for Prosperity and a Secure Retirement
2 days
Caught in the middle of a political battle, @BlackRock reaffirmed its focus is helping millions of Americans save for retirement. They warned that injecting politics from either side risks undermining financial performance.
Tweet card summary image
prosperityretirementalliance.com
Millions of Ameircans depend on the security of their retirement savings to live with dignity after a lifetime of hard work. Thatโ€™s why the Alliance for Prosperity and a Secure Retirement (APSR)...
1
0
2
@IASLC
IASLC
11 days
On a new episode of Lung Cancer Considered, host @NarjustFlorezMD talks w/ @BRicciutiMD & @g_mountzios about resistance to immune checkpoint inhibitors, STK11/KEAP1/KRAS co-mutations, and emerging NSCLC therapeutics. ๐ŸŽ™๏ธ Listen:
Tweet media one
1
13
28
@IASLC
IASLC
13 days
Ready to advance thoracic oncology in Asia? Join us at the 2025 IASLC Asia Conference on Lung Cancer (ACLC) in Ho Chi Minh City, Vietnam, from October 9โ€“11, 2025! . Focused on regional priorities: Biomarker testing, early detection with low-dose CT & AI, targeted therapies,
Tweet media one
0
7
16
@IASLC
IASLC
14 days
In this episode of #LungCancerConsidered in Cantonese, @mollylisc speaks with Dr. Rina Hui and Dr. Zhang Li about diagnosis, treatment strategies, and multidisciplinary care of EGFR-mutant NSCLC. ๐ŸŽง Listen now: #NSCLC #EGFR
Tweet media one
1
8
18
@IASLC
IASLC
16 days
Zongertinib is now FDA approved for HER2+ NSCLC, but where does it fit in care?. On #LungCancerConsidered, @NarjustFlorezMD talks with @IbiayiMD & Dr. Gerrina Ruiter about the data behind this approval and its role in treating HER2-positive NSCLC. ๐ŸŽง
Tweet media one
0
8
26
@IASLC
IASLC
20 days
Ready to transform the future of lung cancer care?. Join global experts at #WCLC2025, the worldโ€™s leading lung cancer conference, September 6โ€“9 in Barcelona, Spain. Dive into groundbreaking research and therapy trends, connect with top clinicians and researchers, and elevate
Tweet media one
10
18
48
@IASLC
IASLC
21 days
What is it like to be an Arabic woman building a career in thoracic oncology? On this episode of #LungCancerConsidered in Arabic, @NaglaAKarimMD, @asrar_alahmadi & @MayaKKhalil discuss their professional journeys & the impact of representation in the field. ๐ŸŽง
Tweet media one
5
8
20
@IASLC
IASLC
24 days
What happens when artificial intelligence meets lung cancer research? On #LungCancerConsidered, @StephenVLiu talks with @PrelajArsela about the promiseโ€”and limitationsโ€”of AI in transforming how we study and treat lung cancer. ๐ŸŽง #AI #LungCancer
Tweet media one
1
13
31
@IASLC
IASLC
24 days
Have you registered yet? . Join global experts at the IASLC 2025 Asia Conference on Lung Cancer, Oct 9โ€“11 in Ho Chi Minh City! . Advance your knowledge, connect with peers, and help shape the future of lung cancer care. #ACLC2025 #LungCancer #IASLC
Tweet media one
1
1
7
@IASLC
IASLC
28 days
This #WorldLungCancerDay, we want to hear from you:. ๐Ÿ’ฌ Why do you choose to study, advocate, research, or educate about lung cancer? Whether itโ€™s personal, professional, or both, your story matters. Drop a reply and let us know. ๐Ÿซ #LungCancerAwareness #Oncology.
4
1
15
@IASLC
IASLC
29 days
Only 1 Week Left! ๐Ÿ•ž.Want to co-lead WCLC 2027 in Denver? Applications for Conference Co-Chairs close on August 6. Donโ€™t miss your chance to be at the forefront of lung cancer research and care. Apply now! . #conference #cochairs #denver #lungcancer #IASLC
Tweet media one
1
8
25
@IASLC
IASLC
29 days
How is EGFR-mutant NSCLC managed in Romania? ๐Ÿ‡ท๐Ÿ‡ดIn this episode of #LungCancerConsidered in Romanian, @mihaela_aldea speaks with Dr. Miruna Grecea & Dr. Andrei Ungureanu about diagnosis, multidisciplinary care & post-CRT consolidation with osimertinib. ๐ŸŽง
Tweet media one
0
4
18
@IASLC
IASLC
30 days
๐Ÿ”ฌ Is there a new model for future clinical trials?. Learn how Pragmatica-Lung helped streamline data collection and improve patient diversity in a new ILCN article.
Tweet media one
0
6
8